Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 267 of the 268 references it cites were found in a registry or an index.

Natural killer cells in cancer biology and therapy

Open access
Wu, Song-Yang, Fu, Tong, Jiang, Yi-Zhou, Shao, Zhi-Ming · 2020 · Molecular Cancer

Abstract

The tumor microenvironment is highly complex, and immune escape is currently considered an important hallmark of cancer, largely contributing to tumor progression and metastasis. Named for their capability of killing target cells autonomously, natural killer (NK) cells serve as the main effector cells toward cancer in innate immunity and are highly heterogeneous in the microenvironment. Most current treatment options harnessing the tumor microenvironment focus on T cell-immunity, either by promoting activating signals or suppressing inhibitory ones. The limited success achieved by T cell immunotherapy highlights the importance of developing new-generation immunotherapeutics, for example utilizing previously ignored NK cells. Although tumors also evolve to resist NK cell-induced cytotoxicity, cytokine supplement, blockade of suppressive molecules and genetic engineering of NK cells may overcome such resistance with great promise in both solid and hematological malignancies. In this review, we summarized the fundamental characteristics and recent advances of NK cells within tumor immunometabolic microenvironment, and discussed potential application and limitations of emerging NK cell-based therapeutic strategies in the era of presicion medicine.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12943-020-01238-x

Cites

267 of 267 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Development and subgroups of NK cells. In bone marrow, NK cells develop from hematopoietic stem cells (HSCs) through common lymphoid progenitors (CLPs) and NK cell precursors (NKPs), and then migrate to peripheral blood (cNK cells) or tissue (trNK cells). The differentiation of trNK-cells occurs in distinct tissue sites, including the lung, thymus, liver, uterus, skin, subcutaneous adipose tissue, and kidney. In these sites, NK cells have different phenotypic features and functions, which constitute the circulation of NK cells at different stages of maturation. CLA, cutaneous lymphocyte-associated antigen; CCR8, C-C motif chemokine receptor 8; GATA3, GATA binding protein 3; CXCR6, C-X-C motif chemokine receptor 6; KIR, killer cell immunoglobulin-like receptor; CILCP, common innate-like cell precursor
Fig. 1 Development and subgroups of NK cells. In bone marrow, NK cells develop from hematopoietic stem cells (HSCs) through common lymphoid progenitors (CLPs) and NK cell precursors (NKPs), and then migrate to peripheral blood (cNK cells) or tissue (trNK cells). The differentiation of trNK-cells occurs in distinct tissue sites, including the lung, thymus, liver, uterus, skin, subcutaneous adipose tissue, and kidney. In these sites, NK cells have different phenotypic features and functions, which constitute the circulation of NK cells at different stages of maturation. CLA, cutaneous lymphocyte-associated antigen; CCR8, C-C motif chemokine receptor 8; GATA3, GATA binding protein 3; CXCR6, C-X-C motif chemokine receptor 6; KIR, killer cell immunoglobulin-like receptor; CILCP, common innate-like cell precursorCC BY · PubMed Central
Fig. 2 The complex interaction between NK cells and the extracellular matrix. Exposure of NK cells to the adjacent cells, molecules and metabolites in the extracellular matrix affects their development, maturation, activation and functions. CXCR3, C-X-C motif chemokine receptor 3; NKG2D, nature-killer group 2, member D; IFN-γ, interferon γ; TNF-α, tumor necrosis factor α; IDO, indoleamine 2,3-dioxygenase; MICA, MHC class I polypeptide-related sequence A; PGE2, prostaglandin E2; HCC, hepatocellular carcinoma; CIS, cytokine-inducible SH2-containg protein; TGF-β, transforming growth factor-β; HMGB1, high-mobility group box 1; HIF-1α, hypoxia inducible factor-1α; 27HC, 27-hydroxycholesterol; iNKT, invariant natural killer T; GM2, β-N-acetylhexosaminidase; TCR, T cell receptor
Fig. 2 The complex interaction between NK cells and the extracellular matrix. Exposure of NK cells to the adjacent cells, molecules and metabolites in the extracellular matrix affects their development, maturation, activation and functions. CXCR3, C-X-C motif chemokine receptor 3; NKG2D, nature-killer group 2, member D; IFN-γ, interferon γ; TNF-α, tumor necrosis factor α; IDO, indoleamine 2,3-dioxygenase; MICA, MHC class I polypeptide-related sequence A; PGE2, prostaglandin E2; HCC, hepatocellular carcinoma; CIS, cytokine-inducible SH2-containg protein; TGF-β, transforming growth factor-β; HMGB1, high-mobility group box 1; HIF-1α, hypoxia inducible factor-1α; 27HC, 27-hydroxycholesterol; iNKT, invariant natural killer T; GM2, β-N-acetylhexosaminidase; TCR, T cell receptorCC BY · PubMed Central
Fig. 3 Interplay between cancer cells and NK cells during tumorigenesis. The interaction between tumor cells and NK cells changes continuously with NK cell development, tumor progression and metastasis. During the stage of tumorigenesis (a), NK cells recognize tumor cells through various surface molecules and switch to the active status. In the immune control stage (b), NK cells exert killing effects by ADCC, secreting cytokines and generating memory NK cells. Meanwhile, changes in the surface molecules of tumor cells also promote anti-tumor metabolic responses. However, long-term exposure of NK cells to tumor cells, tumor- derived molecules and tumor-educated stromal cells, including fibroblast, monocyte and macrophage, causes NK cells to be in an immunosuppressive state, thereby promoting tumor immune escape and metastasis (c). MHC- I, major histocompatibility complex-I; MICA, MHC class I polypeptide-related sequence A; MICB, MHC class I polypeptide-related sequence B; NCR, natural cytotoxicity receptor; Nfil3, nuclear factor interleukin-3-regulated protein; Id2, inhibitor of DNA binding 2; Tox, thymocyte selection associated high mobility group box; EOMES, eomesodermin; T-bet, T-box transcription factor 21; ADCC, antibody-dependent cell-mediated cytotoxicity; GM-CSF, granulocyte-macrophage colony stimulating factor; PRF1, perforin 1; GZMB, granzyme B; PD-L1, programmed cell death ligand 1; PGE-2, prostaglandin E2; HCC, Hepatocellular Carcinoma; IFN, interfron; TNFα, Tumor Necrosis Factor α;PI3K, Class IA phosphatidylinositol 3 kinase
Fig. 3 Interplay between cancer cells and NK cells during tumorigenesis. The interaction between tumor cells and NK cells changes continuously with NK cell development, tumor progression and metastasis. During the stage of tumorigenesis (a), NK cells recognize tumor cells through various surface molecules and switch to the active status. In the immune control stage (b), NK cells exert killing effects by ADCC, secreting cytokines and generating memory NK cells. Meanwhile, changes in the surface molecules of tumor cells also promote anti-tumor metabolic responses. However, long-term exposure of NK cells to tumor cells, tumor- derived molecules and tumor-educated stromal cells, including fibroblast, monocyte and macrophage, causes NK cells to be in an immunosuppressive state, thereby promoting tumor immune escape and metastasis (c). MHC- I, major histocompatibility complex-I; MICA, MHC class I polypeptide-related sequence A; MICB, MHC class I polypeptide-related sequence B; NCR, natural cytotoxicity receptor; Nfil3, nuclear factor interleukin-3-regulated protein; Id2, inhibitor of DNA binding 2; Tox, thymocyte selection associated high mobility group box; EOMES, eomesodermin; T-bet, T-box transcription factor 21; ADCC, antibody-dependent cell-mediated cytotoxicity; GM-CSF, granulocyte-macrophage colony stimulating factor; PRF1, perforin 1; GZMB, granzyme B; PD-L1, programmed cell death ligand 1; PGE-2, prostaglandin E2; HCC, Hepatocellular Carcinoma; IFN, interfron; TNFα, Tumor Necrosis Factor α;PI3K, Class IA phosphatidylinositol 3 kinaseCC BY · PubMed Central
Fig. 4 Possible targets harnessing NK cells in cancer therapy. In order to obtain better clinical efficacy and reduced severe adverse events, the development of NK cell-based therapies that support NK cell maintenance (a), enhance NK cell function (b) and harness abnormal immunometabolic and intracellular microenvironment (c) is essential. rhIL-12/15/18, recombinant human interleukin-12/15/18; CAR-iPS, chimeric antigen receptor-induced pluripotent stem cell; MIC: MHC I chain related molecule; MICA, MHC class I polypeptide-related sequence A; MICB, MHC class I polypeptide-related sequence B; PD-L1, programmed cell death-ligand 1;scFv, single-chain variable fragment; TSA, tumor specific antigen; BiKE, bispecific killer cell engager; TriKE, trispecific killer engager; CAR-NK, chimeric antigen receptor-nature kill; PD-1, programmed cell death protein 1; MerTK, MER proto-oncogene, tyrosine kinase; 27HC, 27-hydroxycholesterol; GLUT1, glucotransporter 1; MCT1, monocarboxylate transporter 1
Fig. 4 Possible targets harnessing NK cells in cancer therapy. In order to obtain better clinical efficacy and reduced severe adverse events, the development of NK cell-based therapies that support NK cell maintenance (a), enhance NK cell function (b) and harness abnormal immunometabolic and intracellular microenvironment (c) is essential. rhIL-12/15/18, recombinant human interleukin-12/15/18; CAR-iPS, chimeric antigen receptor-induced pluripotent stem cell; MIC: MHC I chain related molecule; MICA, MHC class I polypeptide-related sequence A; MICB, MHC class I polypeptide-related sequence B; PD-L1, programmed cell death-ligand 1;scFv, single-chain variable fragment; TSA, tumor specific antigen; BiKE, bispecific killer cell engager; TriKE, trispecific killer engager; CAR-NK, chimeric antigen receptor-nature kill; PD-1, programmed cell death protein 1; MerTK, MER proto-oncogene, tyrosine kinase; 27HC, 27-hydroxycholesterol; GLUT1, glucotransporter 1; MCT1, monocarboxylate transporter 1CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 268 references

Research works printed but not linked: 3

  1. Cantoni C, Bottino C, Augugliaro R, Morelli L, Marcenaro E, Castriconi R, Vitale M, Pende D, Sivori S, Millo R, et al. Molecular and functional characterization of IRp60, a member of the immunoglobulin superfamily that functions as an inhibitory receptor in human NK cells. Eur J Immunol. 1999;29:3148–59. · doi:10.1002/(sici)1521-4141(199910)29:10<3148::aid-immu3148>3.0.co;2-l
  2. Deniz G, Akdis M, Aktas E, Blaser K, Akdis CA. Human NK1 and NK2 subsets determined by purification of IFN-gamma-secreting and IFN-gamma-nonsecreting NK cells. Eur J Immunol. 2002;32:879–84. · doi:10.1002/1521-4141(200203)32:3<879::aid-immu879>3.0.co;2-2
  3. Chiossone L, Dumas P-Y, Vienne M, Vivier E. Natural killer cells and other innate lymphoid cells in cancer. Nature Reviews Immunol. 2018;18:671–88. · DOI · Paper page

Cited by

See all 911

Metadata

Authors
Wu, S.-Y., Fu, T., Jiang, Y.-Z., & Shao, Z.-M.
Affiliations
Shanghai Medical College of Fudan University (CN)
Corresponding author
  • Jiang, Yi-Zhou
  • Shao, Zhi-Ming
Venue
Molecular Cancer
Published
2020-08-06
Volume
19
Issue
1
Pages
120-120
ISSN
1476-4598 (ISSN-L)
OpenAlex
W3046958019
Cited by
863
References
268
Citations by year
2026: 77 · 2025: 199 · 2024: 219 · 2023: 170 · 2022: 122 · 2021: 70 · 2020: 5
FWCI
8.96
Type
journal article
Language
en
Open access
Licence
Locations
  • Molecular Cancer (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Natural Science Foundation of China (81572583, 81874112, 81874113, 81502278, 81922048)
  • Shanghai Education Development Foundation (17CG01)
  • Fudan University
  • Shanghai Municipal Education Commission (17CG01)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
Keywords
natural killer cells, tumor microenvironment, immune evasion, NK cell therapy, NK cell resistance, tumor immunometabolism, NK cell engineering, innate immunity, hematologic malignancies, solid tumors, precision medicine
MeSH terms
Animals, Disease Susceptibility, Energy Metabolism, Humans, Immunity, Innate, Immunotherapy, Killer Cells, Natural, Neoplasms, Signal Transduction, Biomarkers, Disease Progression, Disease Management, Immunomodulation, Tumor Microenvironment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Natural killer cells in cancer biology and therapy. https://app.cochat.ai/papers/10.1186/s12943-020-01238-x
The paper
Wu, S.-Y., Fu, T., Jiang, Y.-Z., & Shao, Z.-M. (2020). Natural killer cells in cancer biology and therapy. Molecular Cancer. https://doi.org/10.1186/s12943-020-01238-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.